US4539154A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polyene compounds
Assignee: F Hoffmann La Roche AG
•
Filing: 1983-06-15
•
Granted: 1985-09-03
•
Expires: 2003-06-15
Abstract
Abstract 9-(cyclohexenyl or phenyl)-4,7-dimethyl-2,4,6,8-nonatetraenoic acid derivatives as well as 7-(5,6,7,8-tetrahydro-5,5,8,8,-tetramethyl-2-naphthyl)-4-methyl-2,4,6- octatrienoic acid derivatives useful for the treatment of neoplasms, premalignant lesions, acne, psoriasis and rheumatic diseases of an inflammatory or degenerative kind.
Inventors
- 👤 Ernst P. Krebs
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 11:27
CPC Classifications
C; C07; C07C; C07C403/00; C07C403/20; C07C57/00; C07C57/26; C07C57/30; C07C57/46; C07C57/50; C07B; C07B2200/00; C07B2200/09; C07C2601/00; C07C2601/12; C07C2601/16
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
80 words
A composition of matter selected from the group consisting of compounds of the formula: ##STR9## where R 1 is selected from the group consisting of ##STR10## R 2 is hydroxy, lower alkoxy, amino, mono(lower alkyl)amino, or di(lower alkyl)amino; R 3 is lower alkyl or halogen, R 4 is lower alkyl; R 5 is lower alkoxy; R 6 is hydrogen or lower alkyl and R 7 is lower alkyl or halogen and pharmaceutically acceptable salts thereof when R 2 is hydroxy.
Claim 2
Dependent Claim
80 words
A composition of matter selected from the group consisting of compounds of the formula: ##STR9## where R 1 is selected from the group consisting of ##STR10## R 2 is hydroxy, lower alkoxy, amino, mono(lower alkyl)amino, or di(lower alkyl)amino; R 3 is lower alkyl or halogen, R 4 is lower alkyl; R 5 is lower alkoxy; R 6 is hydrogen or lower alkyl and R 7 is lower alkyl or halogen and pharmaceutically acceptable salts thereof when R 2 is hydroxy.
Claim 3
Dependent Claim
10 words
The composition of claim 1 wherein R 1 is ##STR11##
Claim 4
Dependent Claim
10 words
The composition of claim 2 wherein R 2 is hydroxy.
Claim 5
Dependent Claim
11 words
The composition of claim 3 wherein said compound is (all-E)-4-methyl-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2,4,6-octatrienoic acid.
Claim 6
Dependent Claim
11 words
The composition of claim 2 wherein R 2 is lower alkoxy.
Claim 7
Dependent Claim
11 words
The composition of claim 5 wherein said compound is ethyl (all-E)-4-methyl-7-(5,6,7,8-tetrahydro-5,5,8,8tetramethyl-2-naphthyl)-2,4,6-octatrienoate.
Claim 8
Dependent Claim
11 words
The composition of claim 2 wherein R 2 is mono(lower alkyl)amino.
Claim 9
Dependent Claim
11 words
The composition of claim 3 wherein said compound is N-ethyl 4-methyl-7-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-2,4,6-octatrienamide.
Claim 10
Dependent Claim
10 words
The compound of claim 1 wherein R 1 is ##STR12##
Claim 11
Dependent Claim
10 words
The composition of claim 9 wherein R 2 is hydroxy.
Claim 12
Dependent Claim
11 words
The composition of claim 10 wherein said compound is 4,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid.
Claim 13
Dependent Claim
11 words
The composition of claim 9 wherein R 2 is lower alkoxy.
Claim 14
Dependent Claim
11 words
The composition of claim 12 wherein said compound is ethyl 4,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
Claim 15
Dependent Claim
28 words
The composition of claim 1 wherein R 1 is ##STR13## wherein R 3 , R 4 , R 5 , R 6 and R 7 are as above.
Claim 16
Dependent Claim
27 words
The composition of claim 14 wherein R 3 , R 4 and R 7 are lower alkyl, R 5 is lower alkoxy and R 6 is hydrogen.
Claim 17
Dependent Claim
10 words
The composition of claim 15 wherein R 2 is hydroxy.
Claim 18
Dependent Claim
11 words
The composition of claim 16 wherein said compound is (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-4,7-dimethyl-2,4,6,8-nonatetraenoic acid.
Claim 19
Dependent Claim
11 words
The composition of claim 15 wherein R 2 is lower alkoxy.
Claim 20
Dependent Claim
11 words
The composition of claim 18 wherein said compound is ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-4,7-dimethyl-2,4,6,8-nonatetraenoate.
References Cited (Backward Citations)
FR2081478A1
Cited
GB1335867A
Cited
US4051174A
Cited
DE2456959A1
Cited
US4105681A
Cited
US4129662A
Cited
US4137246A
Cited
US4225527A
Cited
US4193931A
Cited
US4169103A
Cited
DE2843884A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-09-02 | 1989-03-04 | 1989-09-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-09-02 | 1993-03-04 | 1993-09-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-09-02 | 1997-03-04 | 1997-09-03 | $7700.00 | Window Closed / Lapsed |